Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Lebrest 2.5mg tablets

Ferron Par Pharmaceuticals

Product packaging may vary from one country to another.

Ingredients in every tablet

Letrozole 2.5 mg

Each package contains

3 blisters of 10 tablets

Other details

Dosage formTablet; coated
Flavour None

W.H.O. classification

ATC Level 1 L – Antineoplastic and immunomodulating agents
ATC Level 2 L02 – Endocrine Therapy Antineoplastic and Immunomodulating Agents
ATC Level 3 L02B – Hormone Antagonists and Related Agents

Warnings

Pregnancy

<span class="warning-0 warning-pregnancy">NOT RECOMMENDED</span>This item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

NOT RECOMMENDEDThis item should not be used while operating heavy machinery.

Available in

Indonesia

Dosage information

18 YEARS OLD AND ABOVE
The recommended dose of letrozole is 2.5 mg once daily.

— In the adjuvant and extended adjuvant setting, treatment with letrozole should continue for 3 years or until tumor relapse occurs, whichever comes first.

— In patients with metastatic disease, treatment with letrozole should continue until tumor progression is evident.

Food does not affect the absorption of letrozole and the drug may be
administered without regard to meals.

ELDERLY PATIENTS
No dose adjustment is required for elderly patients.

PATIENTS WITH HEPATIC IMPAIRMENT
No dosage adjustment is required for patients with mild to moderate hepatic impairment.

PATIENTS WITH RENAL IMPAIRMENT
No dosage adjustment is required for patients with mild to moderate renal impairment (creatinine clearance ≥10 ml/minute).

Indication

– Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer Extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. Treatment in postmenopausal women with hormone-dependent advanced breast cancer. Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antiestrogens. Preoperative therapy in postmenopausal women with localized hormone receptor positive breast cancer, to allow subsequent breast-conserving surgery in women not originally considered candidates for this type of surgery. Subsequent treatment after surgery should be in accordance with standard of care.